Related Experiment Video
Updated: Feb 6, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors
Enrico Derenzini1, Patrizia Mondello2, Tatiana Erazo2
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Oncohematology Unit, European Institute of Oncology, Milan, Italy.
Abstract:
The phosphatidylinositol 3 kinase (PI3K)-glycogen synthase kinase β (GSK3β) axis plays a central role in MYC-driven lymphomagenesis, and MYC targeting with bromodomain and extraterminal protein family inhibitors (BETi) is a promising treatment strategy in lymphoma. In a high-throughput combinatorial drug screening experiment, BETi enhance the antiproliferative effects of PI3K inhibitors in a panel of diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma cell lines. BETi or MYC silencing upregulates several PI3K pathway genes and induces GSK3β S9 inhibitory phosphorylation, resulting in increased β-catenin protein abundance. Furthermore, BETi or MYC silencing increases GSK3β S9 phosphorylation levels and β-catenin protein abundance through downregulating the E2 ubiquitin conjugating enzymes UBE2C and UBE2T. In a mouse xenograft DLBCL model, BETi decrease MYC, UBE2C, and UBE2T and increase phospho-GSK3β S9 levels, enhancing the anti-proliferative effect of PI3K inhibitors. Our study reveals prosurvival feedbacks induced by BETi involving GSK3β regulation, providing a mechanistic rationale for combination strategies.
Insights
Bromodomain and extraterminal protein family inhibitors (BETi) combined with PI3K inhibitors show promise for lymphoma treatment. BETi enhance anti-cancer effects by regulating GSK3β and β-catenin pathways, offering new combination strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The PI3K-GSK3β axis is crucial in MYC-driven lymphomagenesis.
- MYC-targeting BET inhibitors are a potential lymphoma treatment.
Purpose of the Study:
- To investigate the combinatorial effects of BET inhibitors and PI3K inhibitors in lymphoma.
- To elucidate the molecular mechanisms underlying BET inhibitor-induced prosurvival feedbacks.
Main Methods:
- High-throughput drug screening of lymphoma cell lines.
- MYC silencing and gene expression analysis.
- Western blotting for protein phosphorylation and abundance.
- Mouse xenograft models for diffuse large B cell lymphoma (DLBCL).
Main Results:
- BET inhibitors synergize with PI3K inhibitors to reduce lymphoma cell proliferation.
- BETi upregulate PI3K pathway genes and increase GSK3β S9 phosphorylation, leading to elevated β-catenin.
- BETi downregulate UBE2C and UBE2T, contributing to GSK3β S9 phosphorylation and β-catenin stabilization.
- In vivo, BETi decrease MYC, UBE2C, UBE2T, and increase phospho-GSK3β S9, enhancing PI3K inhibitor efficacy.
Conclusions:
- BET inhibitors induce prosurvival feedbacks via GSK3β regulation in lymphoma.
- This study provides a mechanistic basis for combining BET inhibitors and PI3K inhibitors in lymphoma therapy.
Related Concept Videos
Feedback Inhibition
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Feedback Loops
Self-Evaluation: Self-Enhancement and Self-Verification
Effects of feedback
Feedback significantly modifies the gain of a control system. The gain of a system without feedback is altered by a factor of one plus GH, where G represents...

